查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
AAV特異性細胞和基因治療生物製造CDMO的全球市場（2023-2033）：按開發階段、工作流程、適應症、培養類型和區域進行分析和預測
市場調查報告書
商品編碼
1335235

AAV特異性細胞和基因治療生物製造CDMO的全球市場（2023-2033）：按開發階段、工作流程、適應症、培養類型和區域進行分析和預測

Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis: Focus on Phase of Development, Workflow, Indication, Culture Type, and Region - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 336 Pages | 商品交期: 1-5個工作天內

價格

全球AAV特異性細胞和基因治療生物製造CDMO市場規模預計將從2022年的2.313億美元成長到2033年的25.666億美元，預測期內年複合成長率為24.61%。

市場的成長預計將受到基於病毒載體的基因治療的臨床活動的活性化以及 CDMO 為推進病毒載體製造和基因治療研究的大量投資而推動。

主要市場統計資料
預測期 2023-2033
2023年評估 2.843 億美元
2033年預測 25.666 億美元
年複合成長率 24.61%

AAV 特異性細胞和基因治療生物製造 CDMO 市場目前處於後期階段。基於 AAV 的基因治療引起了人們的廣泛關注和研究興趣，導致對 CDMO 的需求增加。這種日益成長的興趣是由於基於 AAV 的療法具有治療各種遺傳性疾病和疾病的潛力。

此外，開發商和 CDMO 之間的伙伴關係和合作在加速基於 AAV 的尖端療法的可用性方面發揮著關鍵作用。透過合作，細胞和基因治療公司可以致力於研究和臨床活動，同時將製造外包給 CDMO。這種方法可以快速生產創新療法並將其推向市場。此外，研發方面的大量投資也刺激了該領域的進步，並鼓勵探索新的治療可能性。

本報告調查了全球 AAV 特異性細胞和基因治療生物製造 CDMO 市場，並提供市場定義和概述、市場影響因素和市場機會分析、法規環境競爭市場規模趨勢和預測。形勢、主要企業簡介等

主要企業簡介：

  • AAGC Biologics.
  • Charles River Laboratories International, Inc.
  • Catalent, Inc.
  • Creative Biogene
  • Danaher. (Cytiva)
  • FUJIFILM Diosynth Biotechnologies
  • Genscript Biotech Corporation (GenScript ProBio)
  • Lonza.
  • Merck KGaA
  • Porton Advanced Solution Ltd.
  • PackGene Biotech
  • Oxford Biomedica plc
  • Thermo Fisher Scientific Inc. (Patheon Pharma Services)
  • WuXi AppTec

目錄

第1章 市場

  • 產品定義
  • 市場範圍
  • 調查方法
  • 市場概況
    • 世界市場情景
    • 市場足跡和成長潛力
    • COVID-19 對市場的影響
    • 未滿足的需求

第2章 行業分析

  • 概述
  • 法規指導
  • 歐洲藥品管理局 (EMA)
  • 美國食品藥物管理局（FDA）

第3章 市場動態

  • 概述
  • 影響分析
  • 市場促進因素
  • 市場抑制因素
  • 市場機會

第4章 競爭形勢

  • 概述
  • 關鍵戰略和發展
  • 市場佔有率分析
  • 成長佔有率分析
  • 供應鏈分析

第5章 發展階段

  • 概述
  • 臨床一期
  • 臨床二期
  • 臨床三期
  • 商業階段

第6章 工作流程

  • 概述
  • 上游加工
  • 下游加工
  • 分配/填充/精加工

第7章 適應症

  • 概述
  • 瘤
  • 眼科
  • 感染疾病
  • 代謝紊亂
  • 神經病變
  • 其他

第8章 按文化類型

  • 概述
  • 黏合培養
  • 懸浮培養

第9章 區域

  • 概述
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東/非洲

第10章 公司簡介

  • 生態系統中活躍的公司
  • 公司簡介
Product Code: BHL1415SA

“Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV to Reach $2,566.6 Million by 2033.”

Industry Overview

The global cell and gene therapy biomanufacturing CDMO market - focused on AAV was valued at $231.3 million in 2022 and is anticipated to reach $2,566.6 million by 2033, witnessing a CAGR of 24.61% during the forecast period 2023-2033. The growth in the global cell and gene therapy biomanufacturing CDMO market- focused on AAV is expected to be driven by the rise in clinical activities around viral-vector based gene therapies and high investments of CDMOs in advancing viral-vector manufacturing and research in gene therapies.

Market Lifecycle Stage

The global cell and gene therapy biomanufacturing CDMO market- focused on AAV is currently in a progressing phase. AAV-based gene therapies have gained significant attention and research interest, leading to a higher demand for CDMOs in this market. This increased interest is mainly driven by the potential of AAV-based therapies to treat various genetic disorders and diseases.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$284.3 Million in 2023
2023 Forecast$2,566.6 Million by 2033
CAGR24.61%

Furthermore, partnerships and collaborations between therapy developers and CDMOs play a crucial role in accelerating the availability of cutting-edge AAV-based therapies. By working together, cell and gene therapy developers can focus on their research and clinical activities while outsourcing the manufacturing aspects to CDMOs. This approach enables faster production and time-to-market for these innovative therapies. Additionally, substantial investments in research and development have further fueled advancements in this area, encouraging the exploration of new therapeutic possibilities.

Despite the positive outlook, the global cell and gene therapy biomanufacturing CDMO market- focused on AAV also faces some challenges. One significant challenge is ensuring scalability and maintaining strict quality control standards. As the demand for AAV-based therapies increases, CDMOs need to adapt their manufacturing processes to handle larger production volumes without compromising product quality.

Moreover, the market is becoming more competitive as more CDMOs enter the space to meet the growing demand. This intensified competition could lead to price pressures and potential reductions in profit margins, which may impact the business viability of CDMOs.

Furthermore, the market offers substantial opportunities for all involved parties. Collaborations between CDMOs and therapy developers can drive advancements in AAV biomanufacturing facilities, leading to more efficient and cost-effective production processes. These advancements can further contribute to the overall growth of the market.

Impact

The impact on the global cell and gene therapy biomanufacturing CDMO market- focused on AAV, would be influenced by several factors such as the growing attention and research activities surrounding AAV-based gene therapies would lead to a surge in demand for CDMOs with expertise in AAV biomanufacturing. This increased demand would create more business opportunities for existing CDMOs and attract new players to enter the market. Moreover, the collaborations between therapy developers and CDMOs would foster faster commercialization of AAV-based therapies. This would not only benefit therapy developers by accelerating their time-to-market but also boost the growth of CDMOs, as they establish themselves as reliable partners in the industry. This increasing number of CDMOs entering the market to cater to the rising demand might intensify competition. This could potentially lead to price pressures, as CDMOs may compete to offer competitive rates to secure contracts with therapy developers.

In addition, advancements in AAV biomanufacturing technology could lead to more efficient and cost-effective production processes. CDMOs that adopt these technological innovations would have a competitive advantage, attracting more clients and expanding their market share. However, ensuring scalability in AAV biomanufacturing would be a significant challenge for CDMOs. The ability to handle larger production volumes while maintaining high-quality standards is crucial to meeting the growing demand. CDMOs that can overcome these challenges effectively would be in a better position to thrive in the market.

Impact of COVID-19

The COVID-19 pandemic has had both major and minor impacts on the cell and gene therapy biomanufacturing CDMO market with a focus on AAV.

Operational disruptions caused by lockdowns, restrictions, and supply chain challenges led to delays in manufacturing processes and project timelines. Moreover, clinical trials involving AAV-based therapies also faced disruptions due to enrollment challenges, site closures, and regulatory hurdles, affecting CDMOs involved in providing services in these trials. The pandemic has highlighted the importance of adaptability and resilience in the biomanufacturing sector and as the situation stabilizes, the industry is expected to recover and continue driving advancements in AAV-based therapies.

The uncertain economic environment resulted in cautious funding and investment decisions, impacting the availability of financial resources for CDMOs, and potentially slowing down their expansion plans and technological advancements. In addition, regulatory processes experienced delays and changes as regulatory agencies, including the FDA, redirected resources to address pandemic-related concerns. This could have affected the approval timelines for AAV-based therapies and the manufacturing activities associated with them.

Market Segmentation:

Segmentation 1: by Phase of Development

  • Clinical Phases I
  • Clinical Phases II
  • Clinical Phases III
  • Commercial Phase

Commercial Phases to Continue its Dominance in the Phase of Development Segment

Based on phase of development, the commercial phase segment dominated the global cell and gene therapy biomanufacturing CDMO market- focused on AAV in FY2022. As more AAV-based therapies continue to advance through clinical phases and gain approval, the commercial phase segment is likely to remain a key driver of growth in the CDMO market.

Segmentation 2: by Workflow

  • Upstream Processing
  • Downstream Processing
  • Formulation, Fill & Finish

Downstream Processing to Continue its Dominance in the Workflow Segment

Based on workflow, the downstream processing segment dominated the global cell and gene therapy biomanufacturing CDMO market- focused on AAV in FY2022. The downstream processing segment encompasses the steps involved after the initial cell culture and vector production, where the focus is on purification, filtration, and isolation of the therapeutic AAV vectors.

Segmentation 3: by Indication

  • Oncology
  • Ophthalmology
  • Infectious Diseases
  • Metabolic Disorder
  • Neurological Disorder
  • Other

Oncology to Continue its Dominance in the Indication Segment

Based on indication, the oncology segment dominated the global cell and gene therapy biomanufacturing CDMO market- focused on AAV in FY2022. The dominance of the oncology segment can be attributed to several factors. Cancer continues to be a significant global health challenge, with a high incidence rate in various regions. The prevalence of cancer and the unmet medical need for effective treatments drove increased research and development in oncology-focused cell and gene therapies

Segmentation 4: by Culture Type

  • Adherent Culture
  • Suspension Culture

Adherent Culture to Continue its Dominance in the Culture Type Segment

Based on culture type, the adherent culture segment segment dominated the global cell and gene therapy biomanufacturing CDMO market- focused on AAV in FY2022. Adherent cell cultures often yield higher cell densities and higher productivity compared to other culture types. This increased productivity is crucial for generating sufficient quantities of AAV vectors needed for commercial production.

Segmentation 5: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

North America cell and gene therapy biomanufacturing CDMO market- focused on AAV is expected to have a market share value of 40.92% in 2022 and is currently the leading contributor to the market. However, the Asia-Pacific region, constituting several emerging economies, is expected to register the highest CAGR of 26.66% during the forecast period, 2023-2033.

Recent Developments in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV

  • In March 2023, Remedium Bio and Biovian Oy collaborated agreement to work together on the development of Remedium's innovative disease modifying AAV gene therapy for Osteoarthritis. This agreement aims to advance the research and production of groundbreaking therapy, potentially offering new treatment options for patients with Osteoarthritis.
  • In March 2023, Porton Advanced Solutions Ltd. Collaborated with DanausGT Biotechnology Co., Ltd. To expedite gene and cell therapy pipelines and develop innovative therapeutics. Porton Advanced, an end-to-end gene and cell therapy service provider, offered comprehensive solutions to DanausGT, including plasmids, viruses, and cell therapy products. The collaboration combined Porton Advanced's expertise with DanausGT's proprietary CRISPR/AAV technology, accelerating the development of cutting-edge Cell and Gene Therapy (CGT) therapeutics.
  • In May 2023, Life Biosciences collaborated with Forge Biologics to advance the development of gene therapies for aging-related diseases. Forge Biologics provided AAV process development, toxicology, cGMP manufacturing, and analytical services using their proprietary platform processes. The collaboration aimed to accelerate the production and delivery of innovative gene therapies for these diseases.
  • In May 2023, AGC Biologics introduced its BravoAAV viral vector platforms, which provided rapid, efficient, and consistent clinical and commercial GMP production and release. These platforms capitalized on AGC Biologics' extensive experience in Adeno-Associated Viral vector (AAV) development, manufacturing, and analytical expertise accumulated over three decades.
  • In March 2023, Charles River Laboratories Inc., launched a Helper Plasmid to streamline the manufacturing process of AAV vectors. This development aimed to enhance efficiency and simplify the production of AAV vectors, a crucial component in gene therapy manufacturing.

Demand - Drivers, Restraints and Opportunities

Market Demand Drivers:

  • Rise in Preclinical and Clinical Activities around Viral-Vector Based Gene Therapies Propel the Demand for CDMOs in the Market
  • Increasing Number of Emerging Players in the Cell and Gene Therapy (CGT) Sector Upsurge the Demand for CDMOs Services
  • High Investment of CDMOs in Advancing Viral-vector Manufacturing and Research in Gene Therapies

Market Restraints:

  • Limitations in Development of Analytical Methods for Large-scale Adeno-associated virus (AAV) Biomanufacturing
  • High Cost of Viral-vector Manufacturing Creates a Challenge for Emerging CDMOs player in the Market

Market Opportunities:

  • Development in the Advancements of AAV Biomanufacturing Facilities by Strategic Collaborations of CDMO Services

How can this report add value to an organization?

  • Workflow/Innovation Strategy: The cell and gene therapy biomanufacturing CDMO market- focused on AAV (by clinical phases) comprises clinical phase I, clinical phase II, clinical phase III, and commercial phase. Moreover, the study provides the reader with a detailed understanding of the different stages involved in workflow for manufacturing of AAV-based therapies such as upstream processing, downstream processing, and formulation fill & finish.
  • Growth/Marketing Strategy: Emphasize the CDMO's specialization in AAV-based biomanufacturing for cell and gene therapies. The strategic collaborations with therapy developers, academic institutions, and research organizations to be involved in the early stages of gene therapy development. These partnerships can facilitate long-term relationships and secure a pipeline of projects. In addition, Maintain rigorous quality control standards and ensure compliance with global regulatory requirements.
  • Competitive Strategy: Key players in the global cell and gene therapy biomanufacturing CDMO market - focused on AAV have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global cell and gene therapy biomanufacturing CDMO market - focused on AAV has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The global market for cell and gene therapy biomanufacturing CDMO market- focused on AAV is experiencing substantial growth in coming years. The AAV-based gene therapies have shown significant potential in treating various diseases, leading to a high demand for CDMOs specialized in manufacturing these therapies. Collaborations between therapy developers and CDMOs are expected to accelerate the availability of these groundbreaking treatments, ultimately transforming patient care and revolutionizing treatment of genetic disorders and other serious conditions. As the market evolves, CDMOs must continue to invest in cutting-edge technologies, quality systems, and regulatory compliance to meet the increasing demand for AAV-based cell and gene therapies. The high demand for the therapies is driving the growth of cell and gene therapy CDMO biomanufacturers- focused on AAV and creating ample opportunities for them to expand in various geographies and strengthen their market presence.

Key Companies Profiled:

  • AGC Biologics.
  • Charles River Laboratories International, Inc.
  • Catalent, Inc.
  • Creative Biogene
  • Danaher. (Cytiva)
  • FUJIFILM Diosynth Biotechnologies
  • Genscript Biotech Corporation (GenScript ProBio)
  • Lonza.
  • Merck KGaA
  • Porton Advanced Solution Ltd.
  • PackGene Biotech
  • Oxford Biomedica plc
  • Thermo Fisher Scientific Inc. (Patheon Pharma Services)
  • WuXi AppTec

Table of Contents

1 Markets

  • 1.1 Product Definition
    • 1.1.1 Inclusion Criteria for the Report
    • 1.1.2 Exclusion Criteria for the Report
  • 1.2 Market Scope
    • 1.2.1 Scope of the Work
    • 1.2.2 Key Questions Answered in the Report
  • 1.3 Research Methodology
    • 1.3.1 Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV: Research Methodology
    • 1.3.2 Data Sources
      • 1.3.2.1 Primary Data Sources
      • 1.3.2.2 Secondary Data Sources
    • 1.3.3 Market Estimation Model
      • 1.3.3.1 Criteria for Company Profiling
  • 1.4 Market Overview
    • 1.4.1 Global Market Scenario
      • 1.4.1.1 Realistic Growth Scenario
      • 1.4.1.2 Optimistic Scenario
        • 1.4.1.2.1 Pessimistic Scenario
    • 1.4.2 Market Footprint and Growth Potential
    • 1.4.3 COVID-19 Impact on Market
      • 1.4.3.1 Impact on Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
        • 1.4.3.1.1 COVID-19 Impact: Current Scenario of the Market
        • 1.4.3.1.2 Pre- and Post-COVID-19 Impact Assessment
          • 1.4.3.1.2.1 Pre-COVID-19 Phase
          • 1.4.3.1.2.2 Post-COVID-19 Phase
    • 1.4.4 Unmet Needs
      • 1.4.4.1 Addressing Unmet Needs in the AAV Manufacturing Process
        • 1.4.4.1.1 Upstream Processing
        • 1.4.4.1.2 Downstream Processing

2 Industry Analysis

  • 2.1 Overview
  • 2.2 Regulatory Guidance
    • 2.2.1 Current Good Manufacturing Practice (CGMP) Regulations
      • 2.2.1.1 U.S.
      • 2.2.1.2 Europe
  • 2.3 Quality Aspects of Cell and Gene Therapy by the European Medicines Agency (EMA)
    • 2.3.1 Vector Design
    • 2.3.2 Development Genetics
    • 2.3.3 Drug Substance
      • 2.3.3.1 Manufacture
      • 2.3.3.2 Description of Manufacturing Process and Process Controls
    • 2.3.4 Starting Materials
    • 2.3.5 Characterization
    • 2.3.6 Drug Product
      • 2.3.6.1 Manufacturing of the Drug Product and Process Controls
  • 2.4 U.S. Food and Drug Administration (FDA) Requirements for Viral Vectors
    • 2.4.1 Clinical Safety Evaluations for AAV Vectors

3 Market Dynamics

  • 3.1 Overview
  • 3.2 Impact Analysis
  • 3.3 Market Drivers
    • 3.3.1 Rise in Preclinical and Clinical Activities around Viral-Vector-Based Gene Therapies Propelling the Demand for CDMOs in the Market
    • 3.3.2 Increasing Number of Emerging Players in the Cell and Gene Therapy (CGT) Sector Driving the Demand for CDMO Services
    • 3.3.3 High Investment of CDMOs in Advancing Viral-Vector Manufacturing and Research in Gene Therapies
  • 3.4 Market Restraints
    • 3.4.1 Limitations in the Development of Analytical Methods for Large-Scale Adeno-Associated Virus (AAV) Biomanufacturing
    • 3.4.2 High Cost of Viral-Vector Manufacturing Creating a Challenge for Emerging CDMO Players in the Market
  • 3.5 Market Opportunities
    • 3.5.1 Development in the Advancements of AAV Biomanufacturing Facilities by Strategic Collaborations of CDMO Service Provider Companies

4 Competitive Landscape

  • 4.1 Overview
  • 4.2 Key Strategies and Developments
    • 4.2.1 Synergistic Activities
    • 4.2.2 Product Launches
    • 4.2.3 Acquisitions and Mergers
    • 4.2.4 Product Approvals
    • 4.2.5 Business Expansions, Funding, and Investments
  • 4.3 Market Share Analysis
  • 4.4 Growth-Share Analysis
    • 4.4.1 By Phase of Development
  • 4.5 Supply Chain Analysis
    • 4.5.1 Key Entities in Supply Chain

5 By Phase of Development

  • 5.1 Overview
  • 5.2 Clinical Phase I
  • 5.3 Clinical Phase II
  • 5.4 Clinical Phase III
  • 5.5 Commercial Phase

6 By Workflow

  • 6.1 Overview
  • 6.2 Upstream Processing
  • 6.3 Downstream Processing
  • 6.4 Formulation and Fill and Finish

7 By Indication

  • 7.1 Overview
  • 7.2 Oncology
  • 7.3 Ophthalmology
  • 7.4 Infectious Disease
  • 7.5 Metabolic Disorder
  • 7.6 Neurological Disorder
  • 7.7 Other

8 By Culture Type

  • 8.1 Overview
  • 8.2 Adherent Culture
  • 8.3 Suspension Culture

9 By Region

  • 9.1 Overview
    • 9.1.1 North America
      • 9.1.1.1 North America Market Size and Forecast
        • 9.1.1.1.1 North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.1.1.2 North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.1.1.3 North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.1.1.4 North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.1.2 U.S.
        • 9.1.1.2.1 U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.1.2.2 U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.1.2.3 U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.1.2.4 U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.1.3 Canada
        • 9.1.1.3.1 Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.1.3.2 Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.1.3.3 Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.1.3.4 Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.2 Europe
      • 9.1.2.1 Europe Market Size and Forecast
        • 9.1.2.1.1 Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.2.1.2 Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.2.1.3 Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.2.1.4 Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.2.2 U.K.
        • 9.1.2.2.1 U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.2.2.2 U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.2.2.3 U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.2.2.4 U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.2.3 Germany
        • 9.1.2.3.1 Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.2.3.2 Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.2.3.3 Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.2.3.4 Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.2.4 France
        • 9.1.2.4.1 France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.2.4.2 France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.2.4.3 France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.2.4.4 France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.2.5 Italy
        • 9.1.2.5.1 Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.2.5.2 Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.2.5.3 Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.2.5.4 Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.2.6 Spain
        • 9.1.2.6.1 Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.2.6.2 Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.2.6.3 Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.2.6.4 Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.2.7 Rest-of-Europe
        • 9.1.2.7.1 Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.2.7.2 Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.2.7.3 Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.2.7.4 Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.3 Asia-Pacific
      • 9.1.3.1 Asia-Pacific Market Size and Forecast
        • 9.1.3.1.1 Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.3.1.2 Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.3.1.3 Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.3.1.4 Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.3.2 China
        • 9.1.3.2.1 China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.3.2.2 China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.3.2.3 China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.3.2.4 China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.3.3 Japan
        • 9.1.3.3.1 Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.3.3.2 Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.3.3.3 Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.3.3.4 Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.3.4 India
        • 9.1.3.4.1 India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.3.4.2 India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.3.4.3 India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.3.4.4 India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.3.5 Australia
        • 9.1.3.5.1 Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.3.5.2 Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.3.5.3 Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.3.5.4 Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.3.6 South Korea
        • 9.1.3.6.1 South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.3.6.2 South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.3.6.3 South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.3.6.4 South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.3.7 Rest-of-Asia-Pacific
        • 9.1.3.7.1 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.3.7.2 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.3.7.3 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.3.7.4 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.4 Latin America
      • 9.1.4.1 Latin America Market Size and Forecast
        • 9.1.4.1.1 Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.4.1.2 Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.4.1.3 Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.4.1.4 Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.4.2 Brazil
        • 9.1.4.2.1 Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.4.2.2 Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.4.2.3 Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.4.2.4 Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.4.3 Mexico
        • 9.1.4.3.1 Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.4.3.2 Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.4.3.3 Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.4.3.4 Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.4.4 Rest-of-Latin America
        • 9.1.4.4.1 Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.4.4.2 Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.4.4.3 Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.4.4.4 Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.5 Middle East and Africa
      • 9.1.5.1 Middle East and Africa Market Size and Forecast
        • 9.1.5.1.1 Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.5.1.2 Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.5.1.3 Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.5.1.4 Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.5.2 K.S.A.
        • 9.1.5.2.1 K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.5.2.2 K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.5.2.3 K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.5.2.4 K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.5.3 U.A.E.
        • 9.1.5.3.1 U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.5.3.2 U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.5.3.3 U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.5.3.4 U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.5.4 Israel
        • 9.1.5.4.1 Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.5.4.2 Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.5.4.3 Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.5.4.4 Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.5.5 Turkiye
        • 9.1.5.5.1 Turkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.5.5.2 Turkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.5.5.3 Turkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.5.5.4 Turkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.5.6 South Africa
        • 9.1.5.6.1 South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.5.6.2 South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.5.6.3 South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.5.6.4 South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
      • 9.1.5.7 Rest-of-Middle East and Africa
        • 9.1.5.7.1 Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
        • 9.1.5.7.2 Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
        • 9.1.5.7.3 Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
        • 9.1.5.7.4 Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)

10 Company Profiles

  • 10.1 Overview
  • 10.2 Cell and Gene Therapy Biomanufacturing CDMO - Focused on AAV Ecosystem Active Players
  • 10.3 Company Profiles
    • 10.3.1 AGC Biologics.
      • 10.3.1.1 Company Overview
      • 10.3.1.2 Role of AGC Biologics. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.1.3 Key Competitors
      • 10.3.1.4 Financials
      • 10.3.1.5 Corporate Strategies
        • 10.3.1.5.1 Synergistic Activities
        • 10.3.1.5.2 Business Expansions, Funding, and Investments
      • 10.3.1.6 Business Strategies
        • 10.3.1.6.1 Product Launch
      • 10.3.1.7 Analyst Perspective
    • 10.3.2 Charles River Laboratories International, Inc.
      • 10.3.2.1 Company Overview
      • 10.3.2.2 Role of Charles River Laboratories International, Inc. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.2.3 Key Competitors
      • 10.3.2.4 Financials
      • 10.3.2.5 Corporate Strategies
        • 10.3.2.5.1 Synergistic Activities
        • 10.3.2.5.2 Business Expansions
      • 10.3.2.6 Business Strategies
        • 10.3.2.6.1 Product Launches
      • 10.3.2.7 Analyst Perspective
    • 10.3.3 Catalent, Inc.
      • 10.3.3.1 Company Overview
      • 10.3.3.2 Role of Catalent, Inc. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.3.3 Key Competitors
      • 10.3.3.4 Financials
      • 10.3.3.5 Corporate Strategies
        • 10.3.3.5.1 Synergistic Activities
        • 10.3.3.5.2 Business Expansions
      • 10.3.3.6 Business Strategies
        • 10.3.3.6.1 Product Launches/ Approvals
      • 10.3.3.7 Analyst Perspective
    • 10.3.4 Creative Biogene
      • 10.3.4.1 Company Overview
      • 10.3.4.2 Role of Creative Biogene in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.4.3 Analyst Perspective
    • 10.3.5 Danaher. (Cytiva)
      • 10.3.5.1 Company Overview
      • 10.3.5.2 Role of Danaher. (Cytiva) in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.5.3 Key Competitors
      • 10.3.5.4 Financials
      • 10.3.5.5 Key Insights about the Financial Health of the Company
      • 10.3.5.6 Corporate Strategies
        • 10.3.5.6.1 Mergers and Acquisitions
        • 10.3.5.6.2 Synergistic Activities
        • 10.3.5.6.3 Business Expansions
      • 10.3.5.7 Business Strategies
        • 10.3.5.7.1 Product Launches
      • 10.3.5.8 Analyst Perspective
    • 10.3.6 FUJIFILM Diosynth Biotechnologies
      • 10.3.6.1 Company Overview
      • 10.3.6.2 Role of FUJIFILM Diosynth Biotechnologies in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.6.3 Key Competitors
      • 10.3.6.4 Corporate Strategies
        • 10.3.6.4.1 Synergistic Activities
          • 10.3.6.4.1.1 Business Expansions
      • 10.3.6.5 Analyst Perspective
    • 10.3.7 Genscript Biotech Corporation (GenScript ProBio)
      • 10.3.7.1 Company Overview
      • 10.3.7.2 Role of Genscript Biotech Corporation (GenScript ProBio) in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.7.3 Key Competitors
      • 10.3.7.4 Financials
      • 10.3.7.5 Key Insights about the Financial Health of the Company
      • 10.3.7.6 Analyst Perspective
    • 10.3.8 Lonza.
      • 10.3.8.1 Company Overview
      • 10.3.8.2 Role of Lonza. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.8.3 Key Competitors
      • 10.3.8.4 Financials
      • 10.3.8.5 Business Strategies
        • 10.3.8.5.1 Product Launch
      • 10.3.8.6 Analyst Perspective
    • 10.3.9 Merck KGaA
      • 10.3.9.1 Company Overview
      • 10.3.9.2 Role of Merck KGaA in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.9.3 Key Competitors
      • 10.3.9.4 Financials
      • 10.3.9.5 Business Strategies
        • 10.3.9.5.1 Product Launch
      • 10.3.9.6 Analyst Perspective
    • 10.3.10 Porton Advanced Solution Ltd.
      • 10.3.10.1 Company Overview
      • 10.3.10.2 Role of Porton Advanced Solution Ltd. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.10.3 Key Competitors
      • 10.3.10.4 Corporate Strategies
        • 10.3.10.4.1 Synergistic Activities
      • 10.3.10.5 Analyst Perspective
    • 10.3.11 PackGene Biotech
      • 10.3.11.1 Company Overview
      • 10.3.11.2 Role of PackGene Biotech in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.11.3 Key Competitors
      • 10.3.11.4 Analyst Perspective
    • 10.3.12 Oxford Biomedica plc
      • 10.3.12.1 Company Overview
      • 10.3.12.2 Role of Oxford Biomedica plc in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.12.3 Key Competitors
      • 10.3.12.4 Financials
      • 10.3.12.5 Corporate Strategies
        • 10.3.12.5.1 Synergistic Activities
        • 10.3.12.5.2 Business Expansions
      • 10.3.12.6 Analyst Perspective
    • 10.3.13 Thermo Fisher Scientific Inc. (Patheon Pharma Services)
      • 10.3.13.1 Company Overview
      • 10.3.13.2 Role of Thermo Fisher Scientific Inc. (Patheon Pharma Services) in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.13.3 Key Competitors
      • 10.3.13.4 Financials
      • 10.3.13.5 Key Insights about the Financial Health of the Company
      • 10.3.13.6 Corporate Strategies
        • 10.3.13.6.1 Mergers and Acquisitions
        • 10.3.13.6.2 Business Expansions
      • 10.3.13.7 Business Strategies
        • 10.3.13.7.1 Product Launches
      • 10.3.13.8 Analyst Perspective
    • 10.3.14 WuXi AppTec
      • 10.3.14.1 Company Overview
      • 10.3.14.2 Role of WuXi AppTec in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 10.3.14.3 Key Competitors
      • 10.3.14.4 Financials
      • 10.3.14.5 Corporate Strategies
        • 10.3.14.5.1 Mergers and Acquisitions
        • 10.3.14.5.2 Synergistic Activities
      • 10.3.14.6 Business Strategies
        • 10.3.14.6.1 Product Launches
      • 10.3.14.7 Analyst Perspective
    • 10.3.15 Emerging Companies
      • 10.3.15.1 Asklepios BioPharmaceutical, Inc. (AskBio)
      • 10.3.15.2 Forge Biologics
      • 10.3.15.3 Takara Bio, Inc.

List of Figures

  • Figure 1: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 2: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
  • Figure 3: Key Development Analysis from January 2020 to June 2023
  • Figure 4: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), % Share, 2022 and 2033
  • Figure 5: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), % Share, 2022 and 2033
  • Figure 6: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), % Share, 2022 and 2033
  • Figure 7: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), % Share, 2022 and 2033
  • Figure 8: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Region), Market Snapshot
  • Figure 9: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV Segmentation
  • Figure 10: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV: Research Methodology
  • Figure 11: Primary Research Methodology
  • Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 13: Top-Down Approach (Segment-Wise Analysis)
  • Figure 14: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Market Size and Growth Potential (Realistic Scenario), $Million, 2022-2033
  • Figure 15: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Market Size and Growth Potential (Optimistic Scenario), $Million, 2022-2033
  • Figure 16: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Market Size and Growth Potential (Pessimistic Scenario), $Million, 2022-2033
  • Figure 17: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 18: Major Impact
  • Figure 19: Minor Impact
  • Figure 20: Pros and Cons of Upstream Processing
  • Figure 21: Pros and Cons of Downstream Processing
  • Figure 22: Addressing Substantial Challenges in AAV Manufacturing
  • Figure 23: Process of Manufacturing Pharmaceuticals
  • Figure 24: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV: Market Dynamics
  • Figure 25: Clinical Trials in Viral-Vector-Based Gene Therapy from January 2020-May 2023 (by Phase)
  • Figure 26: Number of Cell and Gene Therapy Developers (by Region)
  • Figure 27: Cost of Goods (CoGs) in Manufacturing Scale
  • Figure 28: Cost of Upstream Processing and Downstream Processing in Manufacturing Scales
  • Figure 29: Share of Key Developments, January 2020-June 2023
  • Figure 30: Number of Product Launches (by Company), January 2020-May 2023
  • Figure 31: Market Share Analysis of the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Company), 2022
  • Figure 32: Growth-Share Analysis for Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), 2023-2033
  • Figure 33: Supply Chain Analysis
  • Figure 34: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
  • Figure 35: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), % Share, 2022 and 2033
  • Figure 36: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Clinical Phase I), $Million, 2022-2033
  • Figure 37: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Clinical Phase II), $Million, 2022-2033
  • Figure 38: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Clinical Phase III), $Million, 2022-2033
  • Figure 39: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Commercial Phase), $Million, 2022-2033
  • Figure 40: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
  • Figure 41: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), % Share, 2022 and 2033
  • Figure 42: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Upstream Processing), $Million, 2022-2033
  • Figure 43: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Downstream Processing), $Million, 2022-2033
  • Figure 44: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Formulation and Fill and Finish), $Million, 2022-2033
  • Figure 45: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
  • Figure 46: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), % Share, 2022 and 2033
  • Figure 47: Some Examples of AAV Vectors Employed in Oncology
  • Figure 48: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Oncology), $Million, 2022-2033
  • Figure 49: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Ophthalmology), $Million, 2022-2033
  • Figure 50: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Infectious Disease), $Million, 2022-2033
  • Figure 51: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Metabolic Disorder), $Million, 2022-2033
  • Figure 52: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Neurological Disorder), $Million, 2022-2033
  • Figure 53: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Other), $Million, 2022-2033
  • Figure 54: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
  • Figure 55: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), % Share, 2022 and 2033
  • Figure 56: Adherent Platform
  • Figure 57: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Adherent Culture), $Million, 2022-2033
  • Figure 58: Suspension Platform
  • Figure 59: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Suspension Culture), $Million, 2022-2033
  • Figure 60: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Region)
  • Figure 61: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 62: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
  • Figure 63: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 64: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 65: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 66: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 67: U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 68: U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 69: U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 70: U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 71: U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 72: Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 73: Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 74: Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 75: Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 76: Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 77: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 78: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
  • Figure 79: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 80: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 81: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 82: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 83: U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 84: U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 85: U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 86: U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 87: U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 88: Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 89: Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 90: Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 91: Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 92: Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 93: France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 94: France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 95: France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 96: France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 97: France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 98: Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 99: Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 100: Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 101: Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 102: Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 103: Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 104: Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 105: Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 106: Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 107: Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 108: Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 109: Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 110: Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 111: Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 112: Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 113: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 114: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
  • Figure 115: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 116: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 117: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 118: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 119: China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 120: China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 121: China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 122: China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 123: China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 124: Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 125: Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 126: Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 127: Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 128: Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 129: India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 130: India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 131: India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 132: India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 133: India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 134: Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 135: Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 136: Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 137: Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 138: Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 139: South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 140: South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 141: South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 142: South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 143: South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 144: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 145: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 146: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 147: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 148: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 149: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 150: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
  • Figure 151: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 152: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 153: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 154: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 155: Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 156: Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 157: Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 158: Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 159: Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 160: Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 161: Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 162: Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 163: Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 164: Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 165: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 166: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 167: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 168: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 169: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 170: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 171: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
  • Figure 172: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 173: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 174: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 175: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 176: K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 177: K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 178: K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 179: K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 180: K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 181: U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 182: U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 183: U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 184: U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 185: U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 186: Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 187: Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 188: Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 189: Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 190: Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 191: Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 192: Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 193: Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 194: Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 195: Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 196: South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 197: South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 198: South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 199: South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 200: South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 201: Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
  • Figure 202: Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
  • Figure 203: Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
  • Figure 204: Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
  • Figure 205: Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
  • Figure 206: Total Number of Companies Profiled
  • Figure 207: AGC Biologic s.: Service Portfolio
  • Figure 208: AGC Biologics.: Overall Financials, $Million, 2020-2022
  • Figure 209: AGC Biologics.: Revenue (by Segment), $Million, 2020-2022
  • Figure 210: Charles River Laboratories International, Inc.: Service Portfolio
  • Figure 211: Charles River Laboratories International, Inc.: Overall Financials, $Million, 2020-2022
  • Figure 212: Charles River Laboratories International, Inc.: Revenue (by Segment), $Million, 2020-2022
  • Figure 213: Charles River Laboratories International, Inc.: Revenue (by Region), $Million, 2020-2022
  • Figure 214: Catalent, Inc.: Service Portfolio
  • Figure 215: Catalent, Inc.: Overall Financials, $Million, 2020-2022
  • Figure 216: Catalent, Inc.: Revenue (by Segment), $Million, 2020-2022
  • Figure 217: Catalent, Inc.: Revenue (by Region), $Million, 2020-2022
  • Figure 218: Creative Biogene: Service Portfolio
  • Figure 219: Danaher. (Cytiva): Service Portfolio
  • Figure 220: Danaher. (Cytiva): Overall Financials, $Million, 2020-2022
  • Figure 221: Danaher. (Cytiva): Revenue (by Segment), $Million, 2020-2022
  • Figure 222: Danaher. (Cytiva): Revenue (by Region), $Million, 2020-2022
  • Figure 223: Danaher. (Cytiva): R&D Expenditure, $Million, 2020-2022
  • Figure 224: FUJIFILM Diosynth Biotechnologies: Service Portfolio
  • Figure 225: Genscript Biotech Corporation (GenScript ProBio): Service Portfolio
  • Figure 226: Genscript Biotech Corporation (GenScript ProBio): Overall Financials, $Million, 2020-2022
  • Figure 227: Genscript Biotech Corporation (GenScript ProBio): Revenue (by Segment), $Million, 2020-2022
  • Figure 228: Genscript Biotech Corporation (GenScript ProBio): Revenue (by Region), $Million, 2020-2022
  • Figure 229: Genscript Biotech Corporation (GenScript ProBio): R&D Expenditure, $Million, 2020-2022
  • Figure 230: Lonza.: Service Portfolio
  • Figure 231: Lonza.: Overall Financials, $Million, 2020-2022
  • Figure 232: Lonza.: Revenue (by Segment), $Million, 2021 and 2022
  • Figure 233: Merck KGaA: Service Portfolio
  • Figure 234: Merck KGaA: Overall Financials, $Million, 2020-2022
  • Figure 235: Merck KGaA: Revenue (by Segment), $Million, 2020-2022
  • Figure 236: Merck KGaA: Revenue (by Region), $Million, 2020-2022
  • Figure 237: Porton Advanced Solution Ltd.: Service Portfolio
  • Figure 238: PackGene Biotech: Service Portfolio
  • Figure 239: Oxford Biomedica plc: Service Portfolio
  • Figure 240: Oxford Biomedica plc: Overall Financials, $Million, 2020-2022
  • Figure 241: Oxford Biomedica plc: Revenue (by Segment), $Million, 2020-2022
  • Figure 242: Oxford Biomedica plc: Revenue (by Region), $Million, 2020-2022
  • Figure 243: Thermo Fisher Scientific Inc. (Patheon Pharma Services): Service Portfolio
  • Figure 244: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
  • Figure 245: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
  • Figure 246: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
  • Figure 247: Thermo Fisher Scientific Inc.: R&D Expenditure, 2020-2022
  • Figure 248: WuXi AppTec: Service Portfolio
  • Figure 249: WuXi AppTec: Overall Financials, $Million, 2020-2022
  • Figure 250: WuXi AppTec: Revenue (by Segment), $Million, 2021 and 2022

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Impact Analysis, Market Drivers and Restraints
  • Table 3: Pipeline Analysis of Manufactures in AAV-Based Gene Therapy
  • Table 4: Investment in Viral-Vector Manufacturing
  • Table 5: Limitations Associated with Analytical Method for AAV Quality Control (QC)
  • Table 6: Collaboration and Partnerships
  • Table 7: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
  • Table 8: Pipeline AAV-Based Gene Therapies in the U.S.
  • Table 9: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
  • Table 10: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
  • Table 11: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
  • Table 12: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis